Key result
Long-term outpatient milrinone resolves refractory Fontan-associated PLE with sustained recovery after discontinuation.
Why the study?
Does long-term outpatient milrinone therapy improve ventricular function and resolve protein-losing enteropathy in a patient with refractory Fontan-associated PLE?
Case Report (n=1)
Does long-term outpatient milrinone therapy improve ventricular function and resolve protein-losing enteropathy in a patient with refractory Fontan-associated PLE?
Long-term outpatient milrinone therapy safely resolved refractory Fontan-associated protein-losing enteropathy and improved ventricular function in a 14-year-old patient, demonstrating potential utility as a bridge to recovery.
Answers are grounded in this paper and cite their sources.
Suggests potential benefit of long-term milrinone for refractory post-Fontan PLE; leaves open confirmation in prospective trials.
Protein-losing enteropathy (PLE) occurs in 5% to 18% of post-Fontan palliation patients with a historical mortality rate of 50%. Treatment of PLE continues to be challenging because of limited understanding of its pathophysiology. A 14-year-old boy with double outlet right ventricle and left ventricular hypoplasia with an extracardiac Fontan developed refractory PLE. He was started on long-term, outpatient milrinone at 0.5 μg/kg/min. Over 15 months, ventricular function improved and PLE resolved. Recovery was sustained 8 months after milrinone discontinuation. Milrinone's augmentation of cardiac output and reduction in pulmonary vascular resistance may directly address PLE physiology. Long-term milrinone therapy has primarily been studied as a bridge to transplant. Notably, this case highlights milrinone's use as a bridge to recovery. The 15-month duration of milrinone was safe without adverse outcomes. Long-term outpatient milrinone therapy may serve as a bridge to recovery in patients with refractory Fontan-associated PLE.
No takes yet. Share an insight, caveat, or question.
Breitschopf et al. (2026) conducted a case report in Fontan-associated protein-losing enteropathy (n=1). Milrinone was evaluated on Resolution of protein-losing enteropathy and improvement in ventricular function. Long-term outpatient milrinone resolved refractory Fontan-associated PLE and improved ventricular function, with sustained recovery 8 months after discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: